Show simple item record

dc.contributor.authorLapane, Kate L.
dc.contributor.authorLiu, Shao-Hsien
dc.contributor.authorDube, Catherine E.
dc.contributor.authorDriban, Jeffrey B.
dc.contributor.authorMcAlindon, Timothy E.
dc.contributor.authorEaton, Charles B.
dc.date2022-08-11T08:08:22.000
dc.date.accessioned2022-08-23T15:52:34Z
dc.date.available2022-08-23T15:52:34Z
dc.date.issued2017-02-01
dc.date.submitted2017-11-27
dc.identifier.citationClin Ther. 2017 Feb;39(2):347-358. doi: 10.1016/j.clinthera. 2017 Jan 28. <a href="https://doi.org/10.1016/j.clinthera.2017.01.006">Link to article on publisher's site</a>
dc.identifier.issn0149-2918 (Linking)
dc.identifier.doi10.1016/j.clinthera.2017.01.006
dc.identifier.pmid28139290
dc.identifier.urihttp://hdl.handle.net/20.500.14038/29167
dc.description.abstractPURPOSE: Despite the rapid proliferation of hyaluronate (HA) and corticosteroid (CO) injections and clinical guidelines regarding their use in osteoarthritis (OA), information on the characteristics of people receiving these injections is scarce. We describe the use of injections among adults with radiographically confirmed knee OA and identify factors associated with injection use. METHODS: We used publicly available data from the Osteoarthritis Initiative (OAI), an international collaboration sponsored by the National Institutes of Health, and included participants with > /=1 radiographically confirmed knee OA (Kellgren-Lawrence grade > /=2 [definite osteophytes and possible joint space narrowing (JSN) on anteroposterior weight-bearing radiograph]) at baseline. We matched 415 participants who received at least 1 HA and/or CO injection during the 6-month interval before 1 of the first 7 annual follow-up assessments to 1841 injection nonusers by randomly selecting a study visit to match the distribution observed in the injection users. Multinomial logistic regression models were used for identifying factors associated with injection use, including sociodemographic and clinical/functional factors. FINDINGS: Eighteen percent of the 2256 patients identified as having knee OA had received at least 1 injection (years 1-7, 16.9%, 13.7%, 16.6%, 13.5%, 15.9%, 13.5%, and 9.9%, respectively), most commonly with CO (68.4%). HA and CO were more commonly injected in those with a higher annual household income (adjusted odds ratio [aOR] [95% CI] with HA, US > /=$50,000 vs < $25,000, 3.63; [1.20-10.99]) and less commonly in black patients (HA, 0.19 [0.06-0.55]). Greater Kellgren-Lawrence grade (grade 4 vs 2) was associated with an increased likelihood (aOR [95% CI]) of having received HA (4.79 [2.47-9.30]), CO (1.56 [1.04-2.34]), or both (4.94 [1.99-12.27]). IMPLICATIONS: The receipt of HA or CO injection may be associated with higher socioeconomic positioning and indicators of greater disease severity in patients with knee OA.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28139290&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1016/j.clinthera.2017.01.006
dc.subjectcorticosteroids
dc.subjecthyaluronic acid
dc.subjectintra-articular injections
dc.subjectknee osteoarthritis
dc.subjectlongitudinal studies
dc.subjectClinical Epidemiology
dc.subjectEpidemiology
dc.subjectMusculoskeletal Diseases
dc.subjectOrthopedics
dc.subjectRadiology
dc.titleFactors Associated with the Use of Hyaluronic Acid and Corticosteroid Injections among Patients with Radiographically Confirmed Knee Osteoarthritis: A Retrospective Data Analysis
dc.typeJournal Article
dc.source.journaltitleClinical therapeutics
dc.source.volume39
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1394
dc.identifier.contextkey11150727
html.description.abstract<p>PURPOSE: Despite the rapid proliferation of hyaluronate (HA) and corticosteroid (CO) injections and clinical guidelines regarding their use in osteoarthritis (OA), information on the characteristics of people receiving these injections is scarce. We describe the use of injections among adults with radiographically confirmed knee OA and identify factors associated with injection use.</p> <p>METHODS: We used publicly available data from the Osteoarthritis Initiative (OAI), an international collaboration sponsored by the National Institutes of Health, and included participants with > /=1 radiographically confirmed knee OA (Kellgren-Lawrence grade > /=2 [definite osteophytes and possible joint space narrowing (JSN) on anteroposterior weight-bearing radiograph]) at baseline. We matched 415 participants who received at least 1 HA and/or CO injection during the 6-month interval before 1 of the first 7 annual follow-up assessments to 1841 injection nonusers by randomly selecting a study visit to match the distribution observed in the injection users. Multinomial logistic regression models were used for identifying factors associated with injection use, including sociodemographic and clinical/functional factors.</p> <p>FINDINGS: Eighteen percent of the 2256 patients identified as having knee OA had received at least 1 injection (years 1-7, 16.9%, 13.7%, 16.6%, 13.5%, 15.9%, 13.5%, and 9.9%, respectively), most commonly with CO (68.4%). HA and CO were more commonly injected in those with a higher annual household income (adjusted odds ratio [aOR] [95% CI] with HA, US > /=$50,000 vs < $25,000, 3.63; [1.20-10.99]) and less commonly in black patients (HA, 0.19 [0.06-0.55]). Greater Kellgren-Lawrence grade (grade 4 vs 2) was associated with an increased likelihood (aOR [95% CI]) of having received HA (4.79 [2.47-9.30]), CO (1.56 [1.04-2.34]), or both (4.94 [1.99-12.27]).</p> <p>IMPLICATIONS: The receipt of HA or CO injection may be associated with higher socioeconomic positioning and indicators of greater disease severity in patients with knee OA.</p>
dc.identifier.submissionpathfaculty_pubs/1394
dc.contributor.departmentClinical and Population Health Research Program, Graduate School of Biomedical Sciences
dc.contributor.departmentDepartment of Quantitative Health Sciences, Division of Epidemiology of Chronic Diseases and Vulnerable Populations
dc.source.pages347-358


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record